ClinicalTrials.gg
CompletedNCT01393639Updated Sep 4, 2024Results posted

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

A Phase 2 interventional study of PF-04171327 and PF-04171327 in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 93 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-04.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.

Enrollment
25th of 86
323 · median 155
Started
2011
with 8 others
Phase 2
28 of 152
none open now
Registered
91st of 152
by date

Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 25th largest by enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2011, is one of 28 in phase 2, and was the 91st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Arthritis, Rheumatoid by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. All subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. Study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. The efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • treatment of rheumatoid arthritis
  • treatment of RA
  • patients on methotrexate for rheumatoid arthritis
  • prednisone for rheumatoid arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have documented rheumatoid arthritis with a duration of at least 3 months as determined by the investigator using standardly accepted criteria, must have been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis, and must be free of any signs or symptoms of infection.

Exclusion criteria

Exclusion Criteria:

  • Subjects cannot enter the study if they have recently received treatment with certain medications which might interfere with study medications;
  • subjects cannot enter if they have abnormalities in certain blood tests, history of cancer, recent bone fracture or other significant conditions.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
323 participants (actual)

Study arms

  • Experimental
    PF-04171327 1 mg QD

    Drug: PF-04171327

  • Experimental
    PF-04171327 5 mg QD

    Drug: PF-04171327

  • Experimental
    PF-04171327 10 mg QD

    Drug: PF-04171327

  • Experimental
    PF-04171327 15 mg QD

    Drug: PF-04171327

  • Active comparator
    prednisone 5 mg QD

    Drug: prednisone

  • Active comparator
    prednisone 10 mg QD

    Other: prednisone

  • Placebo comparator
    placebo

    Other: placebo

Interventions

  • 1 mg tablet once daily (QD) for 8 weeks

  • 5 mg tablet once daily (QD) for 8 weeks

  • 10 mg tablet once daily (QD) for 8 weeks

  • 15 mg tablet once daily (QD) for 8 weeks

  • 5 mg capsule once daily for 8 weeks

  • Otherprednisone

    10 mg capsule once daily for 8 weeks

  • Otherplacebo

    placebo (tablet or capsule) once daily (QD) for 8 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8

    ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

    Time frame: Week 8

  2. Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)

    Change from baseline in P1NP at week 8 is presented in this outcome measure.

    Time frame: Week 8

  3. Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)

    Change from baseline in uNTx/uCr at week 8 is presented in this outcome measure.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants Achieving ACR20 Response at Weeks 2, 4, and 12 (Comparisons to Placebo, and Prednisone 10 mg)

    ACR20 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Time frame: Weeks 2, 4, and 12 (taper period)

  2. Percentage of Participants Achieving ACR50 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)

    ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Time frame: Weeks 2, 4, 6, 8, and 12 (taper period)

  3. Percentage of Participants Achieving ACR70 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)

    ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

    Time frame: Weeks 2, 4, 6, 8, and 12 (taper period)

  4. Change From Baseline in Tender-Joint Counts at Weeks 2, 4, 6, 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Time frame: Weeks 2, 4, 6, and 8

  5. Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Time frame: Week 12

  6. Change From Baseline in Swollen-Joint Counts at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Time frame: Weeks 2, 4, 6, and 8

  7. Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)

    Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

    Time frame: Week 12

  8. Change From Baseline in C Reactive Protein (CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo and Prednisone 10 mg)

    The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.

    Time frame: Weeks 2, 4, 6, and 8

  9. Change From Baseline of CRP at Week 12 (Descriptive Statistics)

    The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit.

    Time frame: Week 12

  10. Change From Baseline in Patient Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Time frame: Weeks 2, 4, 6, and 8

  11. Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)

    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

    Time frame: Week 12

  12. Change From Baseline in Physician Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

    Time frame: Weeks 2, 4, 6, and 8

  13. Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)

    The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

    Time frame: Week 12

  14. Change From Baseline in Pain VAS at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.

    Time frame: Weeks 2, 4, 6, and 8

  15. Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics)

    Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.

    Time frame: Week 12

  16. Change From Baseline in HAQ-DI at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Weeks 2, 4, 6, and 8

  17. Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)

    Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Week 12

  18. Change From Baseline in Disease Activity Score (DAS) 28-3 CRP at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

    Time frame: Weeks 2, 4, 6, and 8

  19. Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)

    DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

    Time frame: Week 12

  20. Change From Baseline in DAS28-4(CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.

    Time frame: Weeks 2, 4, 6, and 8

  21. Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)

    DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

    Time frame: Week 12

  22. Change From Baseline in SF-36v2 Mental Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Time frame: Weeks 4 and 8

  23. Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Time frame: Week 12

  24. Change From Baseline in SF-36v2 Physical Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Time frame: Weeks 4 and 8

  25. Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)

    The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

    Time frame: Week 12

07

Results

Posted Sep 4, 2024

Participant flow

This multi-center, randomized, double-blind, parallel-group, active and placebo-controlled study randomized 323 participants in at 73 centers. An additional 34 centers had no screening activities, but received study medication; and an additional 17 centers had at least 1 participant screened, but did not randomize any participants.

Participant flow — Overall Study
MilestonePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Started45474548454647
Completed42404443444439
Not completed3715128
Withdrew: Protocol violation0001000
Withdrew: Other0202101
Withdrew: Withdrawal by subject1100001
Withdrew: Medication error without associated ae0000001
Withdrew: Lost to follow-up0100001
Withdrew: Lack of efficacy0000001
Withdrew: Adverse event2312023

Outcome measures

PrimaryPercentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8

ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8
Percentage of participantsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 847616973517137
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): 10 · 60% CI 5 to 15Superiority criterion versus placebo: Lower bound of 60% credible interval \>20%. Non-responder imputation was used to handle dropouts at Week 8.
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): 24 · 60% CI 18 to 31Superiority criterion versus placebo: Lower bound of 60% credible interval \>20%. Non-responder imputation was used to handle dropouts at Week 8.
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): 32 · 60% CI 25 to 39Superiority criterion versus placebo: Lower bound of 60% credible interval \>20%. Non-responder imputation was used to handle dropouts at Week 8.
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): 36 · 60% CI 29 to 43Superiority criterion versus placebo: Lower bound of 60% credible interval \>20%. Non-responder imputation was used to handle dropouts at Week 8.
  • Prednisone 5 mg vs Placebo · Mean difference (final values): 14 · 60% CI 6 to 22Superiority criterion versus placebo: Lower bound of 60% credible interval \>20%. Non-responder imputation was used to handle dropouts at Week 8.
  • Prednisone 10 mg vs Placebo · Mean difference (final values): 34 · 60% CI 27 to 42Superiority criterion versus placebo: Lower bound of 60% credible interval \>20%. Non-responder imputation was used to handle dropouts at Week 8.
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): -24 · 60% CI -32 to -17Non inferiority criterion versus prednisone 10 mg: Lower bound of 60% credible interval \>-5%. Non-responder imputation was used to handle dropouts at Week 8.
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): -10 · 60% CI -16 to -4Non inferiority criterion versus prednisone 10 mg: Lower bound of 60% credible interval \>-5%. Non-responder imputation was used to handle dropouts at Week 8.
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -2 · 60% CI -9 to 4Non inferiority criterion versus prednisone 10 mg: Lower bound of 60% credible interval \>-5%. Non-responder imputation was used to handle dropouts at Week 8.
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 1 · 60% CI -5 to 8Non inferiority criterion versus prednisone 10 mg: Lower bound of 60% credible interval \>-5%. Non-responder imputation was used to handle dropouts at Week 8.
PrimaryMean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)

Change from baseline in P1NP at week 8 is presented in this outcome measure.

Time frame:
Week 8
Reported as:
Least squares mean · Percent change
Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)
Percent changePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)-3.25 ± 5.50-11.60 ± 5.55-9.96 ± 5.49-16.63 ± 5.55-4.89 ± 5.55-20.14 ± 5.5014.19 ± 5.56
Statistical analysis
  • PF-04171327 1 mg vs Prednisone 5 mg · Mean difference (final values): 1.64 · 95% CI -13.75 to 17.03Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
  • PF-04171327 5 mg vs Prednisone 5 mg · Mean difference (final values): -6.71 · 90% CI -22.16 to 8.75Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
  • PF-04171327 10 mg vs Prednisone 5 mg · Mean difference (final values): -5.07 · 90% CI -20.45 to 10.30Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
  • PF-04171327 15 mg vs Prednisone 5 mg · Mean difference (final values): -11.74 · 90% CI -27.19 to 3.72Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
PrimaryMean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)

Change from baseline in uNTx/uCr at week 8 is presented in this outcome measure.

Time frame:
Week 8
Reported as:
Least squares mean · Percent change
Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)
Percent changePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)6.08 ± 5.83-3.78 ± 5.886.96 ± 5.8615.57 ± 5.832.74 ± 5.87-9.14 ± 5.833.81 ± 5.88
Statistical analysis
  • PF-04171327 1 mg vs Prednisone 5 mg · Mean difference (final values): 3.34 · 95% CI -12.92 to 19.61Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
  • PF-04171327 5 mg vs Prednisone 5 mg · Mean difference (final values): -6.52 · 90% CI -22.86 to 9.81Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
  • PF-04171327 10 mg vs Prednisone 5 mg · Mean difference (final values): 4.22 · 90% CI -12.11 to 20.55Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
  • PF-04171327 15 mg vs Prednisone 5 mg · Mean difference (final values): 12.83 · 90% CI -3.49 to 29.15Statistical analysis was performed using a repeated measures mixed model with fixed effects for treatment and visit, treatment by visit interaction and baseline value; unstructured covariance matrix was used.
SecondaryPercentage of Participants Achieving ACR20 Response at Weeks 2, 4, and 12 (Comparisons to Placebo, and Prednisone 10 mg)

ACR20 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

Time frame:
Weeks 2, 4, and 12 (taper period)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR20 Response at Weeks 2, 4, and 12 (Comparisons to Placebo, and Prednisone 10 mg)
Percentage of ParticipantsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 231.82 ± 7.0232.61 ± 6.9140.00 ± 7.3042.55 ± 7.2128.89 ± 6.7536.96 ± 7.1120.45 ± 6.08
Week 431.11 ± 6.9055.32 ± 7.2566.67 ± 7.0253.19 ± 7.2748.89 ± 7.4565.22 ± 7.0240.00 ± 7.30
Week 1235.56 ± 7.1348.94 ± 7.2955.56 ± 7.4038.30 ± 7.0948.89 ± 7.4556.52 ± 7.3033.33 ± 7.02
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Difference in percentage: 11.36 · 95% CI -6.84 to 29.56Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 12.15 · 95% CI -5.88 to 30.19Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 19.54 · 95% CI 0.91 to 38.17Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 22.09 · 95% CI 3.60 to 40.58Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 8.43 · 95% CI -9.38 to 26.25Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 16.50 · 95% CI -1.84 to 34.84Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: -8.88 · 95% CI -28.58 to 10.80Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 15.31 · 95% CI -4.85 to 35.49Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 26.66 · 95% CI 6.80 to 46.53Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 13.19 · 95% CI -7.01 to 33.40Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 8.88 · 95% CI -11.56 to 29.33Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 25.21 · 95% CI 5.35 to 45.07Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: 2.22 · 95% CI -17.40 to 21.85Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 15.60 · 95% CI -4.24 to 35.45Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 22.22 · 95% CI 2.20 to 42.23Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 4.96 · 95% CI -14.60 to 24.53Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 15.55 · 95% CI -4.51 to 35.63Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 23.18 · 95% CI 3.31 to 43.06Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -5.13 · 95% CI -24.73 to 14.45Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -4.34 · 95% CI -23.79 to 15.09Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 3.04 · 95% CI -16.94 to 23.02Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: 5.59 · 95% CI -14.26 to 25.45Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -34.10 · 95% CI -53.40 to -14.80Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -9.89 · 95% CI -29.68 to 9.88Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 1.44 · 95% CI -18.02 to 20.92Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -12.02 · 95% CI -31.84 to 7.79Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -20.96 · 95% CI -40.98 to -0.94Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -7.58 · 95% CI -27.82 to 12.65Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: -0.96 · 95% CI -21.36 to 19.43Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -18.22 · 95% CI -38.18 to 1.73Non-responder imputation was used to handle dropouts.
SecondaryPercentage of Participants Achieving ACR50 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)

ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

Time frame:
Weeks 2, 4, 6, 8, and 12 (taper period)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR50 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
Percentage of ParticipantsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 24.55 ± 3.148.70 ± 4.158.89 ± 4.2425.53 ± 6.362.22 ± 2.1919.57 ± 5.846.82 ± 3.79
Week 48.89 ± 4.2423.40 ± 6.1735.56 ± 7.1327.66 ± 6.5211.11 ± 4.6830.43 ± 6.7811.11 ± 4.68
Week 611.11 ± 4.6827.66 ± 6.5240.00 ± 7.3042.55 ± 7.2124.44 ± 6.4036.96 ± 7.1115.56 ± 5.40
Week 822.22 ± 6.1931.91 ± 6.7948.89 ± 7.4542.55 ± 7.2126.67 ± 6.5945.65 ± 7.3413.33 ± 5.16
Week 1217.78 ± 5.6921.28 ± 5.9624.44 ± 6.4017.02 ± 5.4826.67 ± 6.5923.91 ± 6.2817.78 ± 5.69
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Difference in percentage: -2.27 · 95% CI -11.93 to 7.38Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 1.87 · 95% CI -9.15 to 12.91Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 2.07 · 95% CI -9.09 to 13.23Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 18.71 · 95% CI 4.19 to 33.23Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: -4.59 · 95% CI -13.19 to 4.00Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 12.74 · 95% CI -0.92 to 26.41Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: -2.22 · 95% CI -14.60 to 10.16Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 12.29 · 95% CI -2.90 to 27.48Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 24.44 · 95% CI 7.71 to 41.17Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 16.54 · 95% CI 0.80 to 32.29Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 0.0 · 95% CI -12.98 to 12.98Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 19.32 · 95% CI 3.16 to 35.48Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: -4.44 · 95% CI -18.46 to 9.57Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 12.10 · 95% CI -4.49 to 28.70Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 24.44 · 95% CI 6.63 to 42.24Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 26.99 · 95% CI 9.33 to 44.65Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 8.88 · 95% CI -7.53 to 25.31Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 21.40 · 95% CI 3.88 to 38.91Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: 8.88 · 95% CI -6.80 to 24.57Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 18.58 · 95% CI 1.96 to 35.20Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 35.55 · 95% CI 17.89 to 53.21Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 29.21 · 95% CI 11.94 to 46.49Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 13.33 · 95% CI -2.96 to 29.63Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 32.31 · 95% CI 14.83 to 49.80Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: 0.00 · 95% CI -15.79 to 15.79Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 3.49 · 95% CI -12.67 to 19.67Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 6.66 · 95% CI -10.13 to 23.47Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: -0.75 · 95% CI -16.25 to 14.74Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 8.88 · 95% CI -8.19 to 25.96Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 6.13 · 95% CI -10.50 to 22.77Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -15.01 · 95% CI -28.03 to -2.00Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -10.86 · 95% CI -24.93 to 3.19Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: -10.67 · 95% CI -24.83 to 3.48Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: 5.96 · 95% CI -10.96 to 22.90Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -21.54 · 95% CI -37.22 to -5.86Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -7.03 · 95% CI -25.01 to 10.95Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 5.12 · 95% CI -14.17 to 24.41Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -2.77 · 95% CI -21.22 to 15.67Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -25.84 · 95% CI -42.54 to -9.14Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -9.29 · 95% CI -28.22 to 9.62Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 3.04 · 95% CI -16.94 to 23.02Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: 5.59 · 95% CI -14.26 to 25.45Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -23.42 · 95% CI -42.26 to -4.59Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -13.73 · 95% CI -33.35 to 5.87Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 3.23 · 95% CI -17.26 to 23.74Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -3.09 · 95% CI -23.27 to 17.07Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -6.13 · 95% CI -22.77 to 10.50Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -2.63 · 95% CI -19.63 to 14.35Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 0.53 · 95% CI -17.06 to 18.12Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -6.89 · 95% CI -23.24 to 9.46Non-responder imputation was used to handle dropouts.
SecondaryPercentage of Participants Achieving ACR70 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)

ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.

Time frame:
Weeks 2, 4, 6, 8, and 12 (taper period)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR70 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
Percentage of ParticipantsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 20.04.352.226.382.228.700.0
Week 40.08.5115.5617.024.4415.220.0
Week 62.2212.7713.3317.026.6721.744.44
Week 88.8917.0226.6721.286.6726.0911.11
Week 126.6712.776.678.5111.1110.876.67
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Difference in percentage: 0.00 · 95% CI 0.00 to 0.00Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 4.34 · 95% CI -1.54 to 10.24Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 2.22 · 95% CI -2.08 to 6.52Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 6.38 · 95% CI -0.60 to 13.37Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 2.22 · 95% CI -2.08 to 6.52Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 8.69 · 95% CI 0.55 to 16.83Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: 0.00 · 95% CI 0.00 to 0.00Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 8.51 · 95% CI 0.53 to 16.48Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 15.55 · 95% CI 4.96 to 26.14Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 17.02 · 95% CI 6.27 to 27.76Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 4.44 · 95% CI -1.57 to 10.46Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 15.21 · 95% CI 4.83 to 25.59Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: -2.22 · 95% CI -9.62 to 5.18Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 8.32 · 95% CI -2.96 to 19.60Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 8.88 · 95% CI -2.72 to 20.50Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 12.57 · 95% CI 0.26 to 24.89Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 2.22 · 95% CI -7.23 to 11.67Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 17.29 · 95% CI 3.94 to 30.64Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: -2.22 · 95% CI -14.60 to 10.16Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 5.91 · 95% CI -8.22 to 20.04Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 15.55 · 95% CI -0.29 to 31.40Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 10.16 · 95% CI -4.70 to 25.03Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: -4.44 · 95% CI -16.16 to 7.27Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 14.97 · 95% CI -0.68 to 30.63Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Placebo · Difference in percentage: 0.00 · 95% CI -10.30 to 10.30Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Placebo · Difference in percentage: 6.09 · 95% CI -5.90 to 18.10Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Placebo · Difference in percentage: 0.00 · 95% CI -10.30 to 10.30Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Placebo · Difference in percentage: 1.84 · 95% CI -8.96 to 12.64Non-responder imputation was used to handle dropouts.
  • Prednisone 5 mg vs Placebo · Difference in percentage: 4.44 · 95% CI -7.27 to 16.16Non-responder imputation was used to handle dropouts.
  • Prednisone 10 mg vs Placebo · Difference in percentage: 4.20 · 95% CI -7.37 to 15.77Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -8.69 · 95% CI -16.83 to -0.55Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -4.34 · 95% CI -14.39 to 5.70Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: -6.47 · 95% CI -15.68 to 2.73Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -2.31 · 95% CI -13.04 to 8.41Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -15.21 · 95% CI -25.59 to -4.83Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -6.70 · 95% CI -19.79 to 6.38Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 0.33 · 95% CI -14.49 to 15.16Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: 1.80 · 95% CI -13.13 to 16.74Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -19.51 · 95% CI -32.19 to -6.84Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -8.97 · 95% CI -24.24 to 6.29Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: -8.40 · 95% CI -23.92 to 7.10Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -4.71 · 95% CI -20.76 to 11.32Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -17.19 · 95% CI -32.36 to -2.02Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: -9.06 · 95% CI -25.69 to 7.56Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: 0.57 · 95% CI -17.53 to 18.68Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -4.81 · 95% CI -22.07 to 12.45Non-responder imputation was used to handle dropouts.
  • PF-04171327 1 mg vs Prednisone 10 mg · Difference in percentage: -4.20 · 95% CI -15.77 to 7.37Non-responder imputation was used to handle dropouts.
  • PF-04171327 5 mg vs Prednisone 10 mg · Difference in percentage: 1.89 · 95% CI -11.21 to 15.00Non-responder imputation was used to handle dropouts.
  • PF-04171327 10 mg vs Prednisone 10 mg · Difference in percentage: -4.20 · 95% CI -15.77 to 7.37Non-responder imputation was used to handle dropouts.
  • PF-04171327 15 mg vs Prednisone 10 mg · Difference in percentage: -2.35 · 95% CI -14.38 to 9.66Non-responder imputation was used to handle dropouts.
SecondaryChange From Baseline in Tender-Joint Counts at Weeks 2, 4, 6, 8 (Comparisons to Placebo, and Prednisone 10 mg)

Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · Joints
Change From Baseline in Tender-Joint Counts at Weeks 2, 4, 6, 8 (Comparisons to Placebo, and Prednisone 10 mg)
JointsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-4.08 ± 0.74-5.55 ± 0.72-4.97 ± 0.73-5.65 ± 0.72-3.88 ± 0.73-5.38 ± 0.72-1.95 ± 0.74
Week 4-5.97 ± 0.80-6.99 ± 0.79-7.01 ± 0.80-6.93 ± 0.79-5.79 ± 0.80-7.44 ± 0.79-4.16 ± 0.80
Week 6-6.87 ± 0.87-8.83 ± 0.87-8.37 ± 0.87-8.31 ± 0.86-6.91 ± 0.87-8.75 ± 0.86-4.64 ± 0.87
Week 8-7.06 ± 0.91-8.65 ± 0.92-9.46 ± 0.91-9.17 ± 0.91-7.00 ± 0.91-8.84 ± 0.90-4.27 ± 0.92
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -2.13 · 95% CI -4.19 to -0.07
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -3.60 · 95% CI -5.63 to -1.57
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -3.02 · 95% CI -5.06 to -0.97
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -3.70 · 95% CI -5.73 to -1.68
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -1.93 · 95% CI -3.97 to 0.12
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -3.43 · 95% CI -5.46 to -1.39
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -1.81 · 95% CI -4.03 to 0.42
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -2.83 · 95% CI -5.04 to -0.62
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -2.85 · 95% CI -5.07 to -0.64
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -2.77 · 95% CI -4.98 to -0.56
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -1.63 · 95% CI -3.85 to 0.59
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -3.27 · 95% CI -5.48 to -1.06
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -2.23 · 95% CI -4.66 to 0.20
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -4.19 · 95% CI -6.62 to -1.77
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -3.73 · 95% CI -6.15 to -1.31
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -3.68 · 95% CI -6.09 to -1.26
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -2.27 · 95% CI -4.69 to 0.16
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -4.11 · 95% CI -6.52 to -1.70
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -2.80 · 95% CI -5.34 to -0.25
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -4.38 · 95% CI -6.93 to -1.83
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -5.20 · 95% CI -7.74 to -2.66
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -4.90 · 95% CI -7.43 to -2.36
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -2.74 · 95% CI -5.28 to -0.20
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -4.57 · 95% CI -7.10 to -2.05
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.30 · 95% CI -0.73 to 3.33
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): -0.17 · 95% CI -2.18 to 1.84
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.41 · 95% CI -1.61 to 2.44
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.27 · 95% CI -2.27 to 1.73
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.47 · 95% CI -0.74 to 3.68
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.45 · 95% CI -1.76 to 2.65
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.42 · 95% CI -1.79 to 2.63
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.51 · 95% CI -1.69 to 2.70
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.88 · 95% CI -0.53 to 4.29
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): -0.08 · 95% CI -2.50 to 2.33
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.38 · 95% CI -2.03 to 2.79
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.43 · 95% CI -1.97 to 2.84
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.78 · 95% CI -0.75 to 4.30
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.19 · 95% CI -2.34 to 2.73
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.62 · 95% CI -3.14 to 1.89
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.33 · 95% CI -2.84 to 2.19
SecondaryChange From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)

Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

Time frame:
Week 12
Reported as:
Mean · Joints
Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)
JointsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)-6.25 ± 6.77-7.24 ± 6.13-6.16 ± 6.40-6.47 ± 7.54-7.07 ± 5.89-8.16 ± 4.66-5.59 ± 6.67
SecondaryChange From Baseline in Swollen-Joint Counts at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · Joints
Change From Baseline in Swollen-Joint Counts at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
JointsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-3.42 ± 0.62-4.70 ± 0.61-4.27 ± 0.62-5.36 ± 0.61-3.65 ± 0.62-5.04 ± 0.61-2.25 ± 0.62
Week 4-5.54 ± 0.70-5.85 ± 0.71-5.94 ± 0.70-7.00 ± 0.70-5.75 ± 0.71-6.71 ± 0.70-3.87 ± 0.70
Week 6-6.26 ± 0.69-6.90 ± 0.70-7.36 ± 0.69-7.68 ± 0.69-6.89 ± 0.69-8.02 ± 0.69-4.94 ± 0.69
Week 8-6.50 ± 0.79-7.45 ± 0.80-7.95 ± 0.79-7.83 ± 0.79-6.90 ± 0.79-8.38 ± 0.78-4.51 ± 0.80
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -1.18 · 95% CI -2.91 to 0.56
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -2.45 · 95% CI -4.17 to -0.73
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -2.03 · 95% CI -3.76 to -0.29
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -3.11 · 95% CI -4.82 to -1.40
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -1.40 · 95% CI -3.13 to 0.33
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -2.80 · 95% CI -4.52 to -1.07
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -1.67 · 95% CI -3.63 to 0.29
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -1.98 · 95% CI -3.94 to -0.01
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -2.07 · 95% CI -4.03 to -0.11
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -3.13 · 95% CI -5.09 to -1.17
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -1.88 · 95% CI -3.85 to 0.09
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -2.84 · 95% CI -4.79 to -0.88
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -1.32 · 95% CI -3.25 to 0.60
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -1.97 · 95% CI -3.90 to -0.04
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -2.43 · 95% CI -4.35 to -0.50
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -2.75 · 95% CI -4.66 to -0.83
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -1.96 · 95% CI -3.88 to -0.03
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -3.08 · 95% CI -5.00 to -1.17
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -1.99 · 95% CI -4.20 to 0.21
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -2.95 · 95% CI -5.17 to -0.72
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -3.44 · 95% CI -5.65 to -1.23
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -3.32 · 95% CI -5.52 to -1.12
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -2.39 · 95% CI -4.60 to -0.18
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -3.87 · 95% CI -6.07 to -1.68
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.62 · 95% CI -0.10 to 3.34
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.34 · 95% CI -1.36 to 2.05
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.77 · 95% CI -0.94 to 2.48
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.31 · 95% CI -2.01 to 1.38
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.17 · 95% CI -0.79 to 3.12
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.86 · 95% CI -1.10 to 2.82
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.76 · 95% CI -1.19 to 2.72
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.29 · 95% CI -2.24 to 1.66
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.76 · 95% CI -0.16 to 3.67
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 1.12 · 95% CI -0.81 to 3.04
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.66 · 95% CI -1.26 to 2.57
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.34 · 95% CI -1.57 to 2.25
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 1.88 · 95% CI -0.31 to 4.07
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.93 · 95% CI -1.28 to 3.13
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.43 · 95% CI -1.76 to 2.62
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.55 · 95% CI -1.63 to 2.74
SecondaryChange From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)

Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.

Time frame:
Week 12
Reported as:
Mean · Joints
Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)
JointsPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)-6.20 ± 6.21-5.98 ± 4.81-5.86 ± 6.17-5.58 ± 6.24-7.43 ± 5.82-7.07 ± 5.02-6.17 ± 5.48
SecondaryChange From Baseline in C Reactive Protein (CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo and Prednisone 10 mg)

The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · mg/L
Change From Baseline in C Reactive Protein (CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo and Prednisone 10 mg)
mg/LPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-7.29 ± 2.89-12.95 ± 2.82-13.73 ± 2.87-18.92 ± 2.78-8.25 ± 2.87-16.90 ± 2.86-2.80 ± 2.89
Week 4-9.77 ± 2.77-14.33 ± 2.78-11.52 ± 2.81-16.57 ± 2.75-3.92 ± 2.81-17.49 ± 2.76-6.35 ± 2.77
Week 6-9.35 ± 2.51-16.16 ± 2.53-13.05 ± 2.49-13.81 ± 2.51-6.54 ± 2.52-16.85 ± 2.46-3.93 ± 2.53
Week 8-7.29 ± 2.49-14.28 ± 2.52-14.86 ± 2.47-11.98 ± 2.49-7.23 ± 2.50-17.59 ± 2.44-4.19 ± 2.49
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -4.49 · 95% CI -12.52 to 3.55
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -10.15 · 95% CI -18.10 to -2.20
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -10.93 · 95% CI -18.94 to -2.92
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -16.12 · 95% CI -24.01 to -8.24
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -5.45 · 95% CI -13.45 to 2.56
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -14.10 · 95% CI -22.09 to -6.11
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -3.42 · 95% CI -11.13 to 4.29
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -7.98 · 95% CI -15.70 to -0.26
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -5.17 · 95% CI -12.93 to 2.59
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -10.22 · 95% CI -17.90 to -2.54
  • Prednisone 5 mg vs Placebo · Mean difference (final values): 2.43 · 95% CI -5.32 to 10.19
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -11.14 · 95% CI -18.83 to -3.45
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -5.42 · 95% CI -12.44 to 1.59
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -12.24 · 95% CI -19.27 to -5.20
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -9.13 · 95% CI -16.11 to -2.14
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -9.88 · 95% CI -16.89 to -2.88
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -2.61 · 95% CI -9.63 to 4.40
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -12.93 · 95% CI -19.88 to -5.98
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -3.10 · 95% CI -10.03 to 3.83
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -10.10 · 95% CI -17.06 to -3.13
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -10.67 · 95% CI -17.57 to -3.77
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -7.79 · 95% CI -14.72 to -0.86
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -3.05 · 95% CI -9.98 to 3.89
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -13.41 · 95% CI -20.27 to -6.54
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 9.61 · 95% CI 1.62 to 17.61
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 3.95 · 95% CI -3.96 to 11.85
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 3.17 · 95% CI -4.80 to 11.13
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -2.03 · 95% CI -9.86 to 5.81
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 7.72 · 95% CI 0.03 to 15.42
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 3.16 · 95% CI -4.54 to 10.87
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 5.97 · 95% CI -1.77 to 13.71
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.92 · 95% CI -6.75 to 8.59
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 7.50 · 95% CI 0.57 to 14.43
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.69 · 95% CI -6.26 to 7.64
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 3.80 · 95% CI -3.09 to 10.70
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 3.05 · 95% CI -3.87 to 9.96
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 10.31 · 95% CI 3.43 to 17.18
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 3.31 · 95% CI -3.59 to 10.22
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 2.73 · 95% CI -4.10 to 9.57
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 5.62 · 95% CI -1.25 to 12.48
SecondaryChange From Baseline of CRP at Week 12 (Descriptive Statistics)

The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit.

Time frame:
Week 12
Reported as:
Mean · mg/L
Change From Baseline of CRP at Week 12 (Descriptive Statistics)
mg/LPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline of CRP at Week 12 (Descriptive Statistics)0.72 ± 27.40-6.24 ± 23.06-4.52 ± 20.35-0.64 ± 29.08-2.90 ± 16.10-9.39 ± 36.10-4.07 ± 22.10
SecondaryChange From Baseline in Patient Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · mm
Change From Baseline in Patient Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
mmPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-10.24 ± 2.85-18.77 ± 2.79-24.72 ± 2.83-22.50 ± 2.77-10.04 ± 2.83-23.51 ± 2.84-10.61 ± 2.85
Week 4-14.93 ± 3.21-24.04 ± 3.22-27.98 ± 3.24-23.14 ± 3.19-17.16 ± 3.24-28.31 ± 3.24-14.56 ± 3.21
Week 6-18.77 ± 3.28-30.84 ± 3.28-35.00 ± 3.27-27.93 ± 3.24-23.07 ± 3.27-32.34 ± 3.27-18.55 ± 3.26
Week 8-16.51 ± 3.49-29.08 ± 3.52-36.88 ± 3.50-31.32 ± 3.47-25.82 ± 3.50-34.60 ± 3.51-18.36 ± 3.51
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): 0.38 · 95% CI -7.56 to 8.31
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -8.15 · 95% CI -16.01 to -0.30
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -14.10 · 95% CI -22.01 to -6.20
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -11.88 · 95% CI -19.70 to -4.06
  • Prednisone 5 mg vs Placebo · Mean difference (final values): 0.58 · 95% CI -7.33 to 8.48
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -12.89 · 95% CI -20.80 to -4.98
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.37 · 95% CI -9.31 to 8.58
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -9.48 · 95% CI -18.43 to -0.53
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -13.42 · 95% CI -22.39 to -4.44
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -8.58 · 95% CI -17.48 to 0.33
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -2.60 · 95% CI -11.57 to 6.38
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -13.75 · 95% CI -22.73 to -4.78
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.22 · 95% CI -9.32 to 8.88
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -12.28 · 95% CI -21.39 to -3.17
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -16.44 · 95% CI -25.53 to -7.36
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -9.38 · 95% CI -18.42 to -0.34
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -4.52 · 95% CI -13.61 to 4.57
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -13.78 · 95% CI -22.87 to -4.69
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): 1.85 · 95% CI -7.90 to 11.60
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -10.72 · 95% CI -20.51 to -0.93
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -18.52 · 95% CI -28.28 to -8.77
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -12.96 · 95% CI -22.67 to -3.25
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -7.46 · 95% CI -17.21 to 2.30
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -16.24 · 95% CI -26.00 to -6.48
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 13.27 · 95% CI 5.34 to 21.20
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 4.74 · 95% CI -3.12 to 12.59
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -1.21 · 95% CI -9.10 to 6.68
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 1.01 · 95% CI -6.79 to 8.81
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 13.39 · 95% CI 4.39 to 22.38
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 4.27 · 95% CI -4.73 to 13.27
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.34 · 95% CI -8.68 to 9.35
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 5.18 · 95% CI -3.77 to 14.12
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 13.56 · 95% CI 4.44 to 22.68
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 1.50 · 95% CI -7.64 to 10.64
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -2.66 · 95% CI -11.76 to 6.44
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 4.41 · 95% CI -4.65 to 13.46
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 18.09 · 95% CI 8.34 to 27.84
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 5.52 · 95% CI -4.27 to 15.32
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -2.28 · 95% CI -12.03 to 7.46
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 3.28 · 95% CI -6.42 to 12.98
SecondaryChange From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)

Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.

Time frame:
Week 12
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
mmPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)-14.54 ± 27.33-22.26 ± 26.11-18.10 ± 25.35-16.74 ± 31.57-19.24 ± 29.32-25.29 ± 29.20-17.90 ± 23.14
SecondaryChange From Baseline in Physician Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · mm
Change From Baseline in Physician Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
mmPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-16.35 ± 2.53-21.74 ± 2.45-22.14 ± 2.48-25.21 ± 2.43-13.24 ± 2.48-22.80 ± 2.48-9.29 ± 2.50
Week 4-22.25 ± 2.68-27.03 ± 2.64-30.72 ± 2.66-28.95 ± 2.62-20.94 ± 2.66-31.16 ± 2.66-15.00 ± 2.64
Week 6-25.58 ± 2.68-32.54 ± 2.67-34.79 ± 2.66-32.79 ± 2.63-28.54 ± 2.66-33.92 ± 2.66-19.48 ± 2.65
Week 8-26.24 ± 2.81-33.92 ± 2.82-38.00 ± 2.79-33.71 ± 2.77-29.25 ± 2.79-35.50 ± 2.79-21.52 ± 2.79
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -7.06 · 95% CI -14.07 to -0.06
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -12.45 · 95% CI -19.34 to -5.56
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -12.85 · 95% CI -19.79 to -5.91
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -15.92 · 95% CI -22.79 to -9.06
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -3.95 · 95% CI -10.89 to 2.99
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -13.51 · 95% CI -20.44 to -6.57
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -7.25 · 95% CI -14.65 to 0.16
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -12.03 · 95% CI -19.38 to -4.68
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -15.72 · 95% CI -23.10 to -8.35
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -13.95 · 95% CI -21.27 to -6.63
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -5.94 · 95% CI -13.31 to 1.43
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -16.16 · 95% CI -23.54 to -8.79
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -6.09 · 95% CI -13.50 to 1.32
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -13.06 · 95% CI -20.46 to -5.65
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -15.31 · 95% CI -22.69 to -7.93
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -13.31 · 95% CI -20.66 to -5.96
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -9.06 · 95% CI -16.44 to -1.68
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -14.44 · 95% CI -21.82 to -7.06
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -4.72 · 95% CI -12.53 to 3.09
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -12.40 · 95% CI -20.21 to -4.59
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -16.48 · 95% CI -24.25 to -8.71
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -12.19 · 95% CI -19.94 to -4.44
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -7.73 · 95% CI -15.50 to 0.04
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -13.98 · 95% CI -21.75 to -6.21
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 6.45 · 95% CI -0.53 to 13.42
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 1.06 · 95% CI -5.81 to 7.92
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.66 · 95% CI -6.25 to 7.57
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -2.42 · 95% CI -9.26 to 4.42
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 8.91 · 95% CI 1.48 to 16.35
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 4.13 · 95% CI -3.24 to 11.51
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.44 · 95% CI -6.96 to 7.84
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 2.21 · 95% CI -5.14 to 9.56
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 8.35 · 95% CI 0.92 to 15.77
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 1.38 · 95% CI -6.03 to 8.80
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.87 · 95% CI -8.26 to 6.52
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 1.13 · 95% CI -6.23 to 8.49
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 9.26 · 95% CI 1.46 to 17.06
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 1.58 · 95% CI -6.23 to 9.38
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -2.50 · 95% CI -10.27 to 5.27
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 1.79 · 95% CI -5.95 to 9.53
SecondaryChange From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)

The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.

Time frame:
Week 12
Reported as:
Mean · mm
Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
mmPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)-25.00 ± 21.57-28.56 ± 26.41-23.04 ± 22.00-24.30 ± 28.15-27.25 ± 23.71-27.25 ± 20.42-19.34 ± 27.21
SecondaryChange From Baseline in Pain VAS at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · mm
Change From Baseline in Pain VAS at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
mmPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-13.41 ± 2.88-17.40 ± 2.83-24.90 ± 2.86-22.86 ± 2.80-12.68 ± 2.86-24.59 ± 2.87-10.54 ± 2.88
Week 4-15.55 ± 3.08-24.38 ± 3.09-29.70 ± 3.10-26.08 ± 3.05-20.26 ± 3.10-29.65 ± 3.11-14.28 ± 3.08
Week 6-19.03 ± 3.33-29.16 ± 3.35-34.37 ± 3.33-30.15 ± 3.30-24.16 ± 3.33-34.69 ± 3.34-18.80 ± 3.32
Week 8-18.95 ± 3.45-28.53 ± 3.50-37.96 ± 3.46-30.91 ± 3.43-25.86 ± 3.46-37.60 ± 3.47-18.26 ± 3.47
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -2.87 · 95% CI -10.89 to 5.14
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -6.86 · 95% CI -14.80 to 1.08
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -14.36 · 95% CI -22.34 to -6.38
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -12.32 · 95% CI -20.22 to -4.41
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -2.14 · 95% CI -10.12 to 5.85
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -14.05 · 95% CI -22.05 to -6.04
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -1.26 · 95% CI -9.83 to 7.30
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -10.10 · 95% CI -18.67 to -1.53
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -15.41 · 95% CI -24.01 to -6.82
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -11.79 · 95% CI -20.33 to -3.26
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -5.98 · 95% CI -14.57 to 2.62
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -15.37 · 95% CI -23.98 to -6.76
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.23 · 95% CI -9.49 to 9.03
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -10.36 · 95% CI -19.64 to -1.08
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -15.57 · 95% CI -24.83 to -6.32
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -11.34 · 95% CI -20.56 to -2.13
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -5.36 · 95% CI -14.61 to 3.89
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -15.88 · 95% CI -25.15 to -6.61
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.69 · 95% CI -10.32 to 8.94
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -10.27 · 95% CI -19.95 to -0.59
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -19.70 · 95% CI -29.34 to -10.06
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -12.65 · 95% CI -22.25 to -3.04
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -7.60 · 95% CI -17.24 to 2.04
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -19.34 · 95% CI -28.99 to -9.68
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 11.17 · 95% CI 3.18 to 19.16
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 7.19 · 95% CI -0.78 to 15.15
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.31 · 95% CI -8.28 to 7.65
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 1.73 · 95% CI -6.14 to 9.61
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 14.11 · 95% CI 5.51 to 22.71
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 5.27 · 95% CI -3.38 to 13.92
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.04 · 95% CI -8.68 to 8.59
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 3.58 · 95% CI -4.99 to 12.15
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 15.65 · 95% CI 6.38 to 24.93
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 5.53 · 95% CI -3.81 to 14.86
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.31 · 95% CI -8.97 to 9.59
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 4.54 · 95% CI -4.69 to 13.77
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 18.65 · 95% CI 9.03 to 28.27
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 9.07 · 95% CI -0.64 to 18.78
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.36 · 95% CI -10.00 to 9.28
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 6.69 · 95% CI -2.91 to 16.29
SecondaryChange From Baseline in Pain VAS at Week 12 (Descriptive Statistics)

Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.

Time frame:
Week 12
Reported as:
Mean · mm
Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics)
mmPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics)-17.86 ± 26.70-19.40 ± 29.04-18.23 ± 27.75-16.60 ± 30.50-21.52 ± 24.69-25.17 ± 29.60-16.30 ± 22.41
SecondaryChange From Baseline in HAQ-DI at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in HAQ-DI at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-0.25 ± 0.06-0.34 ± 0.06-0.33 ± 0.06-0.41 ± 0.06-0.23 ± 0.06-0.41 ± 0.06-0.05 ± 0.06
Week 4-0.26 ± 0.07-0.50 ± 0.07-0.43 ± 0.07-0.51 ± 0.07-0.34 ± 0.07-0.58 ± 0.07-0.14 ± 0.07
Week 6-0.35 ± 0.07-0.60 ± 0.07-0.52 ± 0.07-0.56 ± 0.07-0.39 ± 0.07-0.68 ± 0.07-0.21 ± 0.07
Week 8-0.26 ± 0.08-0.59 ± 0.08-0.60 ± 0.08-0.55 ± 0.08-0.50 ± 0.08-0.77 ± 0.08-0.19 ± 0.08
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.19 · 95% CI -0.37 to -0.02
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.29 · 95% CI -0.46 to -0.11
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -0.28 · 95% CI -0.45 to -0.10
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -0.35 · 95% CI -0.52 to -0.18
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.17 · 95% CI -0.35 to 0.00
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -0.36 · 95% CI -0.53 to -0.18
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.12 · 95% CI -0.31 to 0.07
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.36 · 95% CI -0.54 to -0.17
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -0.28 · 95% CI -0.47 to -0.09
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -0.37 · 95% CI -0.56 to -0.18
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.20 · 95% CI -0.39 to -0.01
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -0.44 · 95% CI -0.63 to -0.25
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.14 · 95% CI -0.34 to 0.05
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.40 · 95% CI -0.59 to -0.20
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -0.32 · 95% CI -0.51 to -0.12
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -0.35 · 95% CI -0.55 to -0.16
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.18 · 95% CI -0.38 to 0.01
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -0.47 · 95% CI -0.67 to -0.27
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.07 · 95% CI -0.30 to 0.15
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.40 · 95% CI -0.63 to -0.18
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -0.41 · 95% CI -0.64 to -0.18
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -0.36 · 95% CI -0.59 to -0.14
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.32 · 95% CI -0.54 to -0.09
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -0.58 · 95% CI -0.81 to -0.35
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.16 · 95% CI -0.01 to 0.34
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.07 · 95% CI -0.10 to 0.24
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.08 · 95% CI -0.10 to 0.25
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.00 · 95% CI -0.17 to 0.18
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.32 · 95% CI 0.13 to 0.51
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.08 · 95% CI -0.11 to 0.27
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.15 · 95% CI -0.04 to 0.34
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.06 · 95% CI -0.13 to 0.25
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.32 · 95% CI 0.13 to 0.52
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.07 · 95% CI -0.12 to 0.27
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.15 · 95% CI -0.05 to 0.35
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.12 · 95% CI -0.08 to 0.31
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.51 · 95% CI 0.28 to 0.73
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.18 · 95% CI -0.05 to 0.40
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.17 · 95% CI -0.06 to 0.40
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.22 · 95% CI -0.01 to 0.44
SecondaryChange From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)

Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)-0.28 ± 0.63-0.57 ± 0.65-0.37 ± 0.50-0.38 ± 0.50-0.52 ± 0.63-0.56 ± 0.59-0.26 ± 0.56
SecondaryChange From Baseline in Disease Activity Score (DAS) 28-3 CRP at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Disease Activity Score (DAS) 28-3 CRP at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-0.81 ± 0.13-1.15 ± 0.13-1.21 ± 0.13-1.51 ± 0.13-0.75 ± 0.13-1.23 ± 0.13-0.40 ± 0.13
Week 4-1.19 ± 0.15-1.49 ± 0.15-1.71 ± 0.15-1.73 ± 0.15-1.01 ± 0.15-1.67 ± 0.15-0.76 ± 0.15
Week 6-1.38 ± 0.16-1.81 ± 0.16-2.01 ± 0.16-1.99 ± 0.16-1.37 ± 0.16-1.98 ± 0.16-0.94 ± 0.16
Week 8-1.44 ± 0.17-1.84 ± 0.17-2.22 ± 0.17-2.13 ± 0.17-1.42 ± 0.17-2.14 ± 0.17-0.93 ± 0.17
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.41 · 95% CI -0.78 to -0.04
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.75 · 95% CI -1.12 to -0.39
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -0.81 · 95% CI -1.18 to -0.44
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -1.11 · 95% CI -1.48 to -0.74
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.35 · 95% CI -0.72 to 0.02
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -0.83 · 95% CI -1.19 to -0.46
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.43 · 95% CI -0.85 to -0.00
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.73 · 95% CI -1.15 to -0.31
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -0.95 · 95% CI -1.37 to -0.52
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -0.96 · 95% CI -1.39 to -0.54
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.24 · 95% CI -0.67 to 0.18
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -0.91 · 95% CI -1.33 to -0.49
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.44 · 95% CI -0.90 to 0.02
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.87 · 95% CI -1.32 to -0.41
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -1.07 · 95% CI -1.53 to -0.62
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -1.05 · 95% CI -1.51 to -0.60
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.43 · 95% CI -0.89 to 0.03
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -1.04 · 95% CI -1.50 to -0.59
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.51 · 95% CI -1.00 to -0.03
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.91 · 95% CI -1.40 to -0.43
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -1.29 · 95% CI -1.77 to -0.80
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -1.20 · 95% CI -1.69 to -0.72
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.49 · 95% CI -0.98 to -0.01
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -1.21 · 95% CI -1.69 to -0.73
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.41 · 95% CI 0.04 to 0.78
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.07 · 95% CI -0.29 to 0.44
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.02 · 95% CI -0.35 to 0.38
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.29 · 95% CI -0.65 to 0.08
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.48 · 95% CI 0.06 to 0.91
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.18 · 95% CI -0.24 to 0.60
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.04 · 95% CI -0.46 to 0.38
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.05 · 95% CI -0.48 to 0.37
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.61 · 95% CI 0.15 to 1.06
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.18 · 95% CI -0.28 to 0.63
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.03 · 95% CI -0.49 to 0.42
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.01 · 95% CI -0.47 to 0.44
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.70 · 95% CI 0.22 to 1.18
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.30 · 95% CI -0.18 to 0.78
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.08 · 95% CI -0.55 to 0.40
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.01 · 95% CI -0.47 to 0.49
SecondaryChange From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)

DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)-1.30 ± 1.21-1.37 ± 1.05-1.29 ± 1.14-1.25 ± 1.36-1.45 ± 1.05-1.62 ± 1.00-1.13 ± 1.08
SecondaryChange From Baseline in DAS28-4(CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)

DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.

Time frame:
Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in DAS28-4(CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 2-0.88 ± 0.14-1.29 ± 0.14-1.45 ± 0.14-1.69 ± 0.14-0.82 ± 0.14-1.46 ± 0.14-0.52 ± 0.14
Week 4-1.29 ± 0.16-1.68 ± 0.16-1.97 ± 0.16-1.90 ± 0.16-1.15 ± 0.16-1.92 ± 0.16-0.90 ± 0.16
Week 6-1.51 ± 0.18-2.06 ± 0.18-2.32 ± 0.18-2.21 ± 0.18-1.56 ± 0.18-2.27 ± 0.18-1.12 ± 0.18
Week 8-1.55 ± 0.19-2.07 ± 0.19-2.53 ± 0.19-2.38 ± 0.19-1.65 ± 0.19-2.44 ± 0.19-1.11 ± 0.19
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.36 · 95% CI -0.76 to 0.03
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.78 · 95% CI -1.17 to -0.39
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -0.93 · 95% CI -1.32 to -0.54
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -1.17 · 95% CI -1.56 to -0.78
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.30 · 95% CI -0.70 to 0.09
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -0.95 · 95% CI -1.34 to -0.55
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.39 · 95% CI -0.84 to 0.07
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.78 · 95% CI -1.23 to -0.32
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -1.06 · 95% CI -1.52 to -0.61
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -1.00 · 95% CI -1.45 to -0.54
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.25 · 95% CI -0.71 to 0.21
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -1.02 · 95% CI -1.48 to -0.57
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.39 · 95% CI -0.89 to 0.11
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.94 · 95% CI -1.44 to -0.45
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -1.21 · 95% CI -1.71 to -0.71
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -1.09 · 95% CI -1.59 to -0.59
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.45 · 95% CI -0.95 to 0.05
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -1.15 · 95% CI -1.65 to -0.66
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -0.44 · 95% CI -0.96 to 0.08
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.96 · 95% CI -1.48 to -0.44
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): -1.43 · 95% CI -1.94 to -0.91
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): -1.28 · 95% CI -1.80 to -0.76
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -0.55 · 95% CI -1.06 to -0.03
  • Prednisone 10 mg vs Placebo · Mean difference (final values): -1.33 · 95% CI -1.85 to -0.81
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.59 · 95% CI 0.19 to 0.98
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.17 · 95% CI -0.22 to 0.56
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.02 · 95% CI -0.38 to 0.41
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.23 · 95% CI -0.62 to 0.16
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.64 · 95% CI 0.18 to 1.09
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.24 · 95% CI -0.21 to 0.70
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.04 · 95% CI -0.50 to 0.42
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.02 · 95% CI -0.43 to 0.48
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.76 · 95% CI 0.26 to 1.26
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.21 · 95% CI -0.29 to 0.70
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.06 · 95% CI -0.55 to 0.44
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.06 · 95% CI -0.43 to 0.56
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): 0.89 · 95% CI 0.37 to 1.41
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): 0.37 · 95% CI -0.15 to 0.89
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -0.09 · 95% CI -0.61 to 0.42
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): 0.05 · 95% CI -0.46 to 0.57
SecondaryChange From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)

DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)-1.39 ± 1.31-1.56 ± 1.17-1.42 ± 1.19-1.38 ± 1.47-1.59 ± 1.22-1.80 ± 1.14-1.29 ± 1.21
SecondaryChange From Baseline in SF-36v2 Mental Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)

The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

Time frame:
Weeks 4 and 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in SF-36v2 Mental Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 43.59 ± 1.284.53 ± 1.265.22 ± 1.305.74 ± 1.253.67 ± 1.297.23 ± 1.294.98 ± 1.28
Week 82.57 ± 1.396.07 ± 1.416.03 ± 1.406.47 ± 1.395.30 ± 1.408.76 ± 1.404.58 ± 1.39
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -1.38 · 95% CI -4.94 to 2.17
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): -0.45 · 95% CI -3.98 to 3.08
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): 0.24 · 95% CI -3.34 to 3.82
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): 0.76 · 95% CI -2.75 to 4.28
  • Prednisone 5 mg vs Placebo · Mean difference (final values): -1.31 · 95% CI -4.88 to 2.27
  • Prednisone 10 mg vs Placebo · Mean difference (final values): 2.25 · 95% CI -1.32 to 5.82
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): -2.01 · 95% CI -5.89 to 1.87
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): 1.49 · 95% CI -2.41 to 5.40
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): 1.45 · 95% CI -2.44 to 5.34
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): 1.89 · 95% CI -1.98 to 5.76
  • Prednisone 5 mg vs Placebo · Mean difference (final values): 0.73 · 95% CI -3.16 to 4.61
  • Prednisone 10 mg vs Placebo · Mean difference (final values): 4.18 · 95% CI 0.29 to 8.06
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): -3.64 · 95% CI -7.21 to -0.06
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): -2.70 · 95% CI -6.25 to 0.85
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -2.01 · 95% CI -5.63 to 1.60
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -1.49 · 95% CI -5.02 to 2.05
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): -6.19 · 95% CI -10.07 to -2.31
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): -2.69 · 95% CI -6.60 to 1.23
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): -2.73 · 95% CI -6.64 to 1.18
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -2.29 · 95% CI -6.16 to 1.58
SecondaryChange From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)

The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)3.35 ± 11.994.19 ± 9.190.48 ± 8.972.72 ± 10.673.08 ± 12.916.11 ± 12.904.69 ± 10.72
SecondaryChange From Baseline in SF-36v2 Physical Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)

The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

Time frame:
Weeks 4 and 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in SF-36v2 Physical Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Week 43.84 ± 0.925.00 ± 0.918.22 ± 0.936.83 ± 0.904.28 ± 0.937.51 ± 0.932.10 ± 0.92
Week 85.24 ± 1.037.85 ± 1.049.65 ± 1.037.15 ± 1.027.06 ± 1.039.62 ± 1.033.45 ± 1.03
Statistical analysis
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): 1.73 · 95% CI -0.83 to 4.30
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): 2.90 · 95% CI 0.35 to 5.45
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): 6.12 · 95% CI 3.54 to 8.70
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): 4.73 · 95% CI 2.19 to 7.26
  • Prednisone 5 mg vs Placebo · Mean difference (final values): 2.18 · 95% CI -0.39 to 4.76
  • Prednisone 10 mg vs Placebo · Mean difference (final values): 5.41 · 95% CI 2.83 to 7.99
  • PF-04171327 1 mg vs Placebo · Mean difference (final values): 1.79 · 95% CI -1.08 to 4.65
  • PF-04171327 5 mg vs Placebo · Mean difference (final values): 4.40 · 95% CI 1.52 to 7.28
  • PF-04171327 10 mg vs Placebo · Mean difference (final values): 6.20 · 95% CI 3.33 to 9.07
  • PF-04171327 15 mg vs Placebo · Mean difference (final values): 3.70 · 95% CI 0.85 to 6.55
  • Prednisone 5 mg vs Placebo · Mean difference (final values): 3.61 · 95% CI 0.74 to 6.47
  • Prednisone 10 mg vs Placebo · Mean difference (final values): 6.17 · 95% CI 3.29 to 9.04
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): -3.68 · 95% CI -6.27 to -1.09
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): -2.51 · 95% CI -5.07 to 0.05
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.71 · 95% CI -1.88 to 3.30
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -0.68 · 95% CI -3.23 to 1.87
  • PF-04171327 1 mg vs Prednisone 10 mg · Mean difference (final values): -4.38 · 95% CI -7.26 to -1.50
  • PF-04171327 5 mg vs Prednisone 10 mg · Mean difference (final values): -1.76 · 95% CI -4.65 to 1.12
  • PF-04171327 10 mg vs Prednisone 10 mg · Mean difference (final values): 0.03 · 95% CI -2.84 to 2.91
  • PF-04171327 15 mg vs Prednisone 10 mg · Mean difference (final values): -2.47 · 95% CI -5.33 to 0.39
SecondaryChange From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)

The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)
Units on a scalePF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)4.64 ± 8.215.39 ± 7.057.42 ± 8.563.91 ± 7.167.63 ± 7.955.85 ± 7.323.23 ± 4.80

Adverse events

Collected over 13 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-04171327 1 mg—0/45 (0%)20/45 (44.4%)
PF-04171327 5 mg—1/47 (2.1%)18/47 (38.3%)
PF-04171327 10 mg—2/45 (4.4%)22/45 (48.9%)
PF-04171327 15 mg—2/48 (4.2%)16/48 (33.3%)
Prednisone 5 mg—0/45 (0%)16/45 (35.6%)
Prednisone 10 mg—2/46 (4.3%)19/46 (41.3%)
Placebo—2/47 (4.3%)16/47 (34%)
Most frequent serious events
Most frequent serious events
EventPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
Coronary artery diseaseCardiac disorders0/450/471/450/480/450/460/47
Spinal compression fractureInjury, poisoning and procedural complications0/450/471/450/480/450/460/47
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/450/470/450/480/451/460/47
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/450/470/450/480/451/460/47
BronchitisInfections and infestations0/450/470/450/480/450/461/47
Cholecystitis infectiveInfections and infestations0/450/470/450/480/450/461/47
GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/451/470/450/480/450/460/47
Chest painGeneral disorders0/450/470/451/480/450/460/47
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/450/470/451/480/450/460/47
Most frequent other events
Showing 10 of 119
Most frequent other events
EventPF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlacebo
ArthralgiaMusculoskeletal and connective tissue disorders1/451/471/450/481/455/460/47
Alanine aminotransferase increasedInvestigations2/451/474/450/480/453/463/47
HeadacheNervous system disorders1/450/470/451/480/454/460/47
NasopharyngitisInfections and infestations1/453/473/452/480/451/461/47
Upper respiratory tract infectionInfections and infestations1/450/473/452/480/450/461/47
ArthritisMusculoskeletal and connective tissue disorders1/450/473/451/480/450/461/47
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/450/470/452/483/450/461/47
HypertensionVascular disorders0/453/470/451/481/450/460/47
Abdominal painGastrointestinal disorders0/450/472/450/481/450/460/47
DiarrhoeaGastrointestinal disorders1/450/470/452/482/452/460/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlaceboTotal
Mean50.4 ± 14.255.1 ± 12.154.7 ± 13.154.0 ± 11.152.9 ± 11.257.3 ± 10.755.2 ± 13.254.3 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)PF-04171327 1 mgPF-04171327 5 mgPF-04171327 10 mgPF-04171327 15 mgPrednisone 5 mgPrednisone 10 mgPlaceboTotal
Female33383437394137259
Male1291111651064
08

Study locations

93 sites
  • Catalina Pointe Clinical Research, Inc.
    Tucson, Arizona 85704, United States
  • C. Michael Neuwelt, MD, Inc.
    San Leandro, California 94578, United States
  • Javed Rheumatology Associates, Inc.
    Newark, Delaware 19713, United States
  • Allergy, Asthma, Arthritis, and Lung Center
    Daytona Beach, Florida 32114, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Alastair C. Kennedy, MD
    Vero Beach, Florida 32960, United States
  • The Center for Arthritis and Rheumatism
    Vero Beach, Florida 32960, United States
  • Arthritis and Osteoporosis Medical Associates, PLLC
    Brooklyn, New York 11201, United States
  • Cincinnati Rheumatic Disease Study Group, Inc.
    Cincinnati, Ohio 45219, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Low Country Rheumatology, PA
    Charleston, South Carolina 29406, United States
  • Tricounty Radiology
    Charleston, South Carolina 29406, United States
  • Accurate Clinical Research, Inc.
    Houston, Texas 77034, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Revmatologichen kabinet, DKTs Sv. Pantaleimon OOD
    Pleven, 5800, Bulgaria
  • Revmatologichno Otdelenie, MBAL - Plovdiv
    Plovdiv, 4000, Bulgaria
  • MBAL "Sveti Ivan Rilski" Sofia; Klinika po Revmatologia
    Sofia, 1612, Bulgaria
  • MBAL Sveti Ivan Rilski Sofia; Klinika po Revmatologia
    Sofia, 1612, Bulgaria
  • Hospital Pablo Tobon Uribe
    Medellin, Antioquia, Colombia
  • Reumalab S.A.S
    Medellin, Antioquia, Colombia
  • Centro Integral de Reumatologia e Inmunologia CIREI
    Bogota, Cundinamarca 110221, Colombia
  • Preventive Care SAS
    Chía, Cundinamarca 250001, Colombia
  • Revmatologie Bruntal, S.R.O.
    Bruntal, 79201, Czechia
  • Revmatologicka ambulance
    Ostrava - Poruba, 70800, Czechia
  • Revmatologicka ambulance
    Praha 4, 140 00, Czechia
  • Thomayerova nemocnice
    Praha 4, 140 59, Czechia
  • Charite Universitaetsmedizin Berlin, Klinik fuer Rheumatologie
    Berlin, 10117, Germany
  • Klinische Forschung Berlin-Buch GmbH
    Berlin, 13125, Germany
  • CIRI GmbH
    Frankfurt am Main, 60528, Germany
  • Dr. Rethy Pal Korhaz es Rendelointezet, II. Reumatologia Szakrendeles
    Bekescsaba, 5600, Hungary
  • Budai Irgalmasrendi Korhaz, Reumatologia I.
    Budapest, 1027, Hungary
  • Revita Reumatologiai Rendelo
    Budapest, 1027, Hungary
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • Fejer Megyei Szent Gyorgy Korhaz Reumatologia
    Szekesfehervar, 8000, Hungary
  • MAV Korhaz es Rendelointezet, Reumatologiai szakrendeles
    Szolnok, 5000, Hungary
  • Krishna Institute of Medical Sciences Ltd
    Secunderabad, Andra Pradesh 500 003, India
  • Shirdi Sai Hospital
    Bangalore, Karnataka 560 054, India
  • Dapartment of Rheumatology
    Lucknow, Uttar Pradesh 226 018, India
  • KyungHee University Hospital
    Seoul, Korea 130-872, Korea, Republic of
  • Daegu Catholic University Medical Center, Department of Rheumatology
    Daegu, 705-718, Korea, Republic of
  • Inha University Hospital, Medicine/Rheumatology
    Incheon, 400-711, Korea, Republic of
  • Seoul National University Hospital, Rheumatology, Internal Medicine
    Seoul, 110-744, Korea, Republic of
  • Konkuk University Medical Center, Department of Rheumatology
    Seoul, 143-729, Korea, Republic of
  • Hospital Raja Permaisuri Bainun
    Ipoh, Perak 30990, Malaysia
  • Sunway Medical Centre
    Petaling Jaya, Selangor Darul Ehsan 46150, Malaysia
  • Centro de Estudios de Investigacion Basica y Clinica SC.
    Guadalajara, Jalisco 44690, Mexico
  • Unidad de Investigacion Biomedica del CEM
    Merida, Yucatan 97000, Mexico
  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.
    San Luis Potosi, 78200, Mexico
  • Centrum Kliniczno-Badawcze J. Brzezicki, B. Górniakiewicz-Brzezicka Lekarze Spółka Partnerska
    Elbląg, 82-300, Poland
  • Nzoz "Lecznica Mak-Med S.C."
    Nadarzyn, 05-830, Poland
  • Wojewodzki Zespol Reumatologiczny im. dr J. Titz-Kosko
    Sopot, 81-759, Poland
  • Spitalul Clinic "Sfanta Maria", Clinica de Medicina Interna si Reumatologie
    Bucuresti, 800578, Romania
  • Spitalul Clinic Judetean de Urgenta "Sfantul Apostol Andrei"
    Galati, 800578, Romania
  • Spitalul Clinic de Recuperare
    Iasi, 700656, Romania
  • Spitalul Clinic Judetean de Urgenta Targu Mures, Reumatologic
    Tg Mures, 540136, Romania
  • Territorial Clinical Hospital
    Barnaul, 656024, Russian Federation
  • Sverdlovsk Regional Clinical Hospital # 1
    Ekaterinburg, 620102, Russian Federation
  • Municilap Institution Central Clinical Hospital 6
    Ekaterinburg, 620149, Russian Federation
  • GBUZ of Kemerovo region Regional clinical hospital for was veterans
    Kemerovo, 650000, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • FSBI Scientific - Research Institute of Rheumatology RAMS n.a. V.A. Nasonova.
    Moscow, 115522, Russian Federation
  • LLC Consultative and Diagnostic Rheumatological Center Healthy Joints
    Novosibirsk, 630091, Russian Federation
  • GBOU VPO "Orenburg State Medical Academy of Ministry of Healthcare of Russian Federation"
    Orenburg, 460000, Russian Federation
  • Republican Hospital V.A.Baranov
    Petrozavodsk, 185019, Russian Federation
  • Ryazan Regional Clinical Cardiological Dispensary
    Ryazan, 390026, Russian Federation
  • Clinical Rheumatological Hospital #25
    Saint-Petersburg, 190068, Russian Federation
  • Clinical Hospital #122 L.G. Sokolov
    Saint-Petersburg, 194291, Russian Federation
  • MUZ City Clinical Hospital #12
    Saratov, 410039, Russian Federation
  • Smolensk Regional Clinical Hospital
    Smolensk, 214018, Russian Federation
  • Tomsk Regional Clinical Hospital
    Tomsk, 634063, Russian Federation
  • Vladimir Regional Clinical Hospital
    Vladimir, 600023, Russian Federation
  • Clinical Hospital of Emergency Care N.V. Soloviev
    Yaroslavl, 150003, Russian Federation
  • Yaroslavl Regional Clinical Hospital
    Yaroslavl, 150062, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Institute for treatment and rehabilitation Niska Banja
    Niska Banja, 18205, Serbia
  • AAGS, s.r.o. , nestatne zdravotnicke zariadenie
    Dunajska Streda, 92901, Slovakia
  • Nestatna reumatologicka ambulancia
    Povazska Bystrica, 017 01, Slovakia
  • Reumatologicka ambulancia, REUMEX, s.r.o.
    Rimavska Sobota, 979 01, Slovakia
  • Reumaglobal s.r.o.
    Trnava, 917 01, Slovakia
  • Nestatna reumatologicka ambulancia
    Zilina, 010 01, Slovakia
  • Panorama Medical Centre
    Panorama, Cape Town 7500, South Africa
  • Emmed Research
    Pretoria, Gauteng 0084, South Africa
  • Hospital SANITAS CIMA.
    Barcelona, 08034, Spain
  • Complejo Hospitalario Universitario A Coruña. Hospital Materno Infantil Teresa Herrera
    La Coruna, 15006, Spain
  • Municipal Medical Institution "City Clinical Hospital #3"
    Chernivtsi, 58022, Ukraine
  • Municipal Medicoprophylactic Institution "Donetsk City Clinical Hospital #5".
    Donetsk, 83001, Ukraine
  • National Scientific Centre "Institute of Cardiology n.a. M.D. Strazheska of NAMS of Ukraine".
    Kiev, 03680, Ukraine
  • Komunalnyi zaklad Kyivskoi oblasnoi rady "Kyivska oblasna klinichna likarnia"
    Kyiv, 04107, Ukraine
  • Komunalnyi zaklad Lvivskoi oblasnoi rady "Lvivskyi oblasnyi klinichnyi diahnostychnyi tsentr"
    Lviv, 79010, Ukraine
  • Komunalna ustanova "Odeska oblasna klinichna likarnia"
    Odesa, 65025, Ukraine
  • Municipal Establishment "City Clinical Hospital #9 n.a. O.I. Minakov", Department of Rheumatology
    Odesa, 65026, Ukraine
  • Vinnytsya regional clinical hospital named after M.I. Pyrogova; Department of rheumatology
    Vinnytsya, 21018, Ukraine
  • Municipal Institution:"Zaporizhzhya Regional Clinical Hospital",Rheumatology Dep.
    Zaporizhzhya, 69600, Ukraine
09

References and documents

Publications

  • Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019. PubMed 31168411 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Jun 2014, 32 months.

Results were first posted in Sep 2024, 10 years 3 months after primary completion. A results delay was requested in Dec 2018.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 32 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2011
First posted
Jul 13, 2011
StartActual
Sep 27, 2011
Primary completionActual
Jun 3, 2014
CompletionActual
Jun 9, 2014
Results delay requested
Dec 12, 2018
Results first posted
Sep 4, 2024
Last update
Sep 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01393639
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Sep 27, 2011
Primary completion
Jun 3, 2014
Completion
Jun 9, 2014
Results posted
Sep 4, 2024
Last update
Sep 4, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fosdagrocorat · Prednisone

Start the discussion